心脏转甲状腺素蛋白淀粉样变性的新分期系统
中位生存期I期69.2个月、II期46.7个月、III期24.1个月(P<0.0001),校正年龄后II期和III期死亡风险显著高于I期,且不受基因型影响。
要点
- 基于NT-proBNP≤3000 ng/L且eGFR≥45 ml/min定义I期,NT-proBNP>3000 ng/L且eGFR<45 ml/min定义III期,其余为II期。
- 中位生存期I期69.2个月、II期46.7个月、III期24.1个月,三期间差异显著(P<0.0001)。
核心结论
- 该简单、普遍适用的分期系统可将ATTRwt和ATTRv心肌病患者分层为不同的预后类别。
研究设计与样本
- 分期系统在法国318例心脏ATTR淀粉样变性患者队列中验证。
主要发现
- 393例(45%)I期患者中位生存期69.2个月,334例(38%)II期患者46.7个月,142例(16%)III期患者24.1个月(P<0.0001)。
- HR和统计学显著性受转甲状腺素蛋白基因型影响很小,并在验证队列中保持一致。
关键数值与推荐
- I期:NT-proBNP≤3000 ng/L且eGFR≥45 ml/min。
- III期:NT-proBNP>3000 ng/L且eGFR<45 ml/min。
- II期:不符合I期或III期标准的其余患者。
临床怎么用
- 该分期系统可用于ATTRwt和ATTRv心肌病患者的预后分层。
- 该分期系统有助于未来新型淀粉样变特异性治疗临床试验的设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Cardiac transthyretin (ATTR) amyloidosis is an increasingly recognized, progressive, and fatal cardiomyopathy, the natural history of which remains unclear. We sought to establish and validate a new prognostic staging system applicable to patients with both wild-type ATTR (ATTRwt) and hereditary variant ATTR (ATTRv) amyloid cardiomyopathy. METHODS AND RESULTS: Eight hundred and sixty-nine patients with cardiac ATTR amyloidosis (553 with ATTRwt and 316 with ATTRv) attending the UK National Amyloidosis Centre were stratified into three disease stages at baseline on the basis of cut points in two universally measured biomarkers, N-terminal pro-B-type natriuretic peptide (NT-proBNP) and estimated glomerular filtration rate (eGFR). Stage I was defined as NT-proBNP ≤3000 ng/L and eGFR ≥45 ml/min, Stage III was defined as NT-proBNP >3000 ng/L and eGFR <45 ml/min, and the remainder were Stage II. The staging system was validated in a cohort of 318 patients with cardiac ATTR amyloidosis from France. Median survival among 393 (45%) Stage I patients was 69.2 months, 334 (38%) Stage II patients was 46.7 months, and 142 (16%) Stage III patients was 24.1 months (P < 0.0001). After adjusting for age, compared with Stage I, the hazard ratio (HR) for death for Stage II was 2.05 [confidence interval (CI) 1.54-2.72, P < 0.001] and for Stage III was 3.80 (CI 2.73-5.28, P < 0.001). HRs and statistical significance were little altered by transthyretin genotype and were maintained in the validation cohort. CONCLUSION: This simple, universally applicable staging system stratifies patients with both ATTRwt and ATTRv amyloid cardiomyopathy into prognostic categories. It will be of value in the design of forthcoming clinical trials of novel amyloid-specific therapies.
引用
- Gillmore JD, Damy T, Fontana M, et al. A new staging system for cardiac transthyretin amyloidosis. Eur Heart J. 2018. PMID: 29048471. doi:10.1093/eurheartj/ehx589
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。